<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51909">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01850030</url>
  </required_header>
  <id_info>
    <org_study_id>M13-563</org_study_id>
    <secondary_id>2012-002215-26</secondary_id>
    <nct_id>NCT01850030</nct_id>
  </id_info>
  <brief_title>A Study to Compare if 30mg/Day of Oral Dydrogesterone is as Tolerable and Safe as 600mg/Day of Intravaginal Capsules for Luteal Support in IVF Pregnancies. This Study Will be Conducted at Several Study Sites and Neither the Patient or the Doctor Know Which of the Two Treatments a Patient Receives</brief_title>
  <acronym>Lotus I</acronym>
  <official_title>A Double-Blind, Double-Dummy, Randomized, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization (Lotus I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Israel: Ethics Commission</authority>
    <authority>Russia: Ethics Committee</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Finland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Female inability to conceive a child. The purpose of this randomized, two-arm and
      double-blind study is to demonstrate that the treatment of a daily dose of 3x10mg
      dydrogesterone orally  is as effective and safe as the daily dose of 3x200 mg micronized
      progesterone capsules administered intravaginally for the luteal support in patients
      undergoing IVF. The treatment will start on the day of oocyte retrieval and continue until
      pregnancy is negative or until week 12 gestation.Patients will be followed during treatment
      until 30 days after delivery to record any safety and tolerability data of the patient and
      their newborn(s).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pregnancy Rate</measure>
    <time_frame>12 weeks´ gestation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pregnancy rate defined as the presence of fetal heart beats at 12 weeks´gestation determined by transvaginal ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive Pregnancy test rate</measure>
    <time_frame>Day 14 after embryo transfer</time_frame>
    <safety_issue>No</safety_issue>
    <description>Positive biochemical pregnancy test on Day 14 after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of successful completion of pregnancy</measure>
    <time_frame>After delivery (about 9 months after IVF)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of live births and healthy newborns</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Study Completion (about 10 months after IVF)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status newborn</measure>
    <time_frame>After delivery (about 9 months after IVF)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The gender, APGAR score, height, weight and head circumference, physical examination and any malformations of the newborn(s) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>At Study Completion (about 10 months after IVF)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Tolerability Data</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1066</enrollment>
  <condition>Female Infertility</condition>
  <arm_group>
    <arm_group_label>Dydrogesterone 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Micronized Progesterone 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone 30 mg</intervention_name>
    <description>Oral Dydrogesterone 10 mg tablets tid</description>
    <arm_group_label>Dydrogesterone 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronized Progesterone 600 mg</intervention_name>
    <description>Intravaginal micronized progesterone 200 mg capsules tid</description>
    <arm_group_label>Micronized Progesterone 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo progesterone</intervention_name>
    <description>Placebo intravaginal micronized progesterone 200 mg capsules tid</description>
    <arm_group_label>Dydrogesterone 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo dydrogesterone</intervention_name>
    <description>placebo oral dydrogesterone 10 mg tablets tid</description>
    <arm_group_label>Micronized Progesterone 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Premenopausal females, age &gt; 18 years &lt; 42 years

          -  Non-smokers. For females who were past smokers, they must have stopped tobacco usage
             for at least 3 months prior baseline visit

          -  Early follicular phase (Day 2-4) FSH (Follicle stimulating hormone) less than or
             equal to 15 IU/L and estradiol (E2)within normal limits

          -  LH (luteinizing hormone), PRL (prolactin), T (testosterone) and TSH
             (thyroid-stimulating hormone), within the normal limits for the clinical laboratory,
             or considered not clinically significant by the Investigator within 6 months prior to
             screening

          -  Documented history of infertility (e.g., unable to conceive for at least one year or
             for 6 months for women ≥ 38 years of age or bilateral tubal occlusion or absence)

          -  Normal transvaginal ultrasound at screening (or within 14 days of screening) without
             evidence of clinically significant abnormality consistent with finding adequate for
             ART with respect to uterus and adnexa (no hydrosalpinx or clinically relevant uterine
             fibroids)

          -  Negative pregnancy test on the day of pituitary down regulation (prior to
             administration of GnRH agonist or GnRH antagonist)

          -  Clinically indicated protocol for induction of IVF with a fresh embryo

          -  Single or dual embryo transfer

          -  BMI ≥ 18 and ≤ 30 kg/m2

        Exclusion Criteria:

          -  Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic,
             hematologic/immunologic, HEENT (head, ears, eyes, nose, throat),
             dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine,
             neurologic/psychiatric, allergy, recent major surgery (&lt; 3 months), or other relevant
             diseases as revealed by history, physical examination and/or laboratory assessments
             which could limit participation in or completion of the study

          -  Acute urogenital disease

          -  Known allergic reactions to progesterone products

          -  Known allergic reactions to peanuts and peanut oil

          -  Intake of experimental drug or participation in any other clinical trial within 30
             days prior to study start

          -  Mental disability or any other lack of fitness, in the Investigator's opinion, to
             preclude subjects to participate in or to complete the study

          -  Current or recent substance abuse, including alcohol and tobacco (Note: Patients who
             stopped tobacco usage at least 3 months prior to screening visit would be allowed)

          -  History of chemotherapy or radiotherapy

          -  Patients with more than 3 unsuccessful IVF attempts

          -  Contraindication for pregnancy

          -  Refusal or inability to comply with the requirements of the study protocol for any
             reason, including scheduled clinic visits and laboratory tests

          -  History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darline Cheatham-Seitz, PhD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esther Oppermann, PhD</last_name>
    <phone>+4951167503954</phone>
    <email>esther.oppermann@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Darline Cheatham-Seitz, PhD, MD</last_name>
    <phone>+4951167502442</phone>
    <email>darline.cheatham-seitz@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site reference no. 113155</name>
      <address>
        <city>Vienna</city>
        <zip>1190</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 113176</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93593</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93598</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93615</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93617</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93613</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93594</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93597</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93616</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93595</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93614</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000884</name>
      <address>
        <city>Helsinki</city>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000885</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000635</name>
      <address>
        <city>Oulu</city>
        <zip>90014</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000795</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000633</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000643</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000645</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000642</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000644</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000883</name>
      <address>
        <city>Luebeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93635</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000934</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000934</name>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93638</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93641</name>
      <address>
        <city>Tel Aviv</city>
        <zip>69710</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000631</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93642</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000630</name>
      <address>
        <city>Moscow</city>
        <zip>117306</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 119916</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. 119915</name>
      <address>
        <city>Baracaldo, Vizcaya</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000791</name>
      <address>
        <city>Barcelona</city>
        <zip>8017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000639</name>
      <address>
        <city>Bilbao</city>
        <zip>48940</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000640</name>
      <address>
        <city>Pozuelo de Alarcon (Madrid)</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000638</name>
      <address>
        <city>Sevilla</city>
        <zip>41011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000637</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>April 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dydrogesterone</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
